Axon Enterprise, Inc. (NASDAQ:AXON) Shares Purchased by Friedenthal Financial

Friedenthal Financial raised its stake in Axon Enterprise, Inc. (NASDAQ:AXON) by 961.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,359 shares of the biotechnology company’s stock after purchasing an additional 1,231 shares during the quarter. Friedenthal Financial’s holdings in Axon Enterprise were worth $808,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of AXON. Quent Capital LLC raised its position in Axon Enterprise by 1,875.0% during the 3rd quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock worth $32,000 after buying an additional 75 shares during the last quarter. Prestige Wealth Management Group LLC raised its holdings in Axon Enterprise by 115.8% during the third quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 44 shares in the last quarter. Brooklyn Investment Group acquired a new stake in Axon Enterprise in the third quarter valued at about $41,000. Planning Capital Management Corp boosted its holdings in Axon Enterprise by 83.3% in the 3rd quarter. Planning Capital Management Corp now owns 121 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 55 shares in the last quarter. Finally, Versant Capital Management Inc increased its position in Axon Enterprise by 4,750.0% during the 4th quarter. Versant Capital Management Inc now owns 97 shares of the biotechnology company’s stock worth $58,000 after purchasing an additional 95 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

Insider Transactions at Axon Enterprise

In other news, insider Jeffrey C. Kunins sold 1,035 shares of the stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $624.47, for a total transaction of $646,326.45. Following the transaction, the insider now directly owns 124,243 shares in the company, valued at $77,586,026.21. This represents a 0.83 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $604.07, for a total transaction of $271,831.50. Following the completion of the sale, the director now owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. The trade was a 6.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 51,545 shares of company stock worth $31,159,317 over the last ninety days. 6.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Needham & Company LLC raised their price target on Axon Enterprise from $525.00 to $600.00 and gave the company a “buy” rating in a report on Friday, November 8th. JMP Securities raised their target price on Axon Enterprise from $430.00 to $500.00 and gave the company a “market outperform” rating in a report on Thursday, October 31st. Morgan Stanley upgraded shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $500.00 to $700.00 in a research note on Tuesday, December 3rd. The Goldman Sachs Group upped their target price on shares of Axon Enterprise from $385.00 to $441.00 and gave the stock a “buy” rating in a research report on Wednesday, October 23rd. Finally, TD Cowen initiated coverage on shares of Axon Enterprise in a research report on Wednesday, January 8th. They set a “buy” rating and a $700.00 price target for the company. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat, Axon Enterprise presently has an average rating of “Moderate Buy” and a consensus price target of $504.92.

Axon Enterprise Price Performance

Axon Enterprise stock traded down $1.32 during midday trading on Monday, reaching $568.68. 421,422 shares of the company were exchanged, compared to its average volume of 688,736. The company has a market capitalization of $43.36 billion, a price-to-earnings ratio of 146.95, a P/E/G ratio of 14.19 and a beta of 1.04. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The firm’s 50-day simple moving average is $607.29 and its 200-day simple moving average is $451.03. Axon Enterprise, Inc. has a 1 year low of $246.99 and a 1 year high of $698.67.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.